Therapeutic duplication would be a concern for a patient prescribed both Eliquis and:

Rationale

Therapeutic duplication would be a concern for a patient prescribed both Eliquis and rivaroxaban.

Eliquis and rivaroxaban are both anticoagulants used to prevent blood clots, and prescribing them together increases the risk of bleeding complications due to therapeutic duplication. This overlap in pharmacological action can lead to adverse effects that outweigh the benefits of treatment.

A (rivaroxaban) CORRECT

Both Eliquis (apixaban) and rivaroxaban belong to the class of direct oral anticoagulants (DOACs). They inhibit factor Xa, a crucial component in the coagulation cascade, which can significantly increase the risk of serious bleeding events if used concurrently. Thus, therapeutic duplication occurs when similar medications are prescribed together, leading to redundant effects.

B (eletriptan) YOUR ANSWER

Eletriptan is a medication used to treat migraine headaches and does not share any therapeutic properties with Eliquis. Since it acts on serotonin receptors rather than affecting blood coagulation pathways, there is no therapeutic duplication concern when these two drugs are prescribed together.

C (eltrombopag) YOUR ANSWER

Eltrombopag is a thrombopoietin receptor agonist used to treat conditions such as chronic immune thrombocytopenia. While it affects platelet production, it does not have anticoagulant properties like Eliquis, making it unrelated in terms of therapeutic duplication. Therefore, using eltrombopag alongside Eliquis does not present the same risks.

D (risperidone) YOUR ANSWER

Risperidone is an atypical antipsychotic used to treat mental health disorders and has no anticoagulant effects. The pharmacological mechanisms of risperidone do not intersect with those of Eliquis, so there is no concern for therapeutic duplication in this case.

Conclusion

Therapeutic duplication occurs when two medications with similar effects are prescribed, which is a significant concern for patient safety. In this case, prescribing both Eliquis and rivaroxaban poses a risk of increased bleeding due to their shared action as anticoagulants. Other listed medications, such as eletriptan, eltrombopag, and risperidone, do not present this risk, as they act through entirely different mechanisms. It is crucial for healthcare providers to recognize and avoid such duplications to ensure patient safety and effective treatment outcomes.

Therapeutic duplication would be a concern for a patient prescribed both Eliquis and:

Therapeutic duplication would be a concern for a patient prescribed both Eliquis and rivaroxaban.

Related Questions

Related Quizzes

How familiar were you with this question?

Report an Issue

Rate this Practice Test